TAG-72: A Protein Interactor with Potential Cancer Treatments

Target Name: Tumor-Associated Glycoprotein 72 (TAG-72)

NCBI ID: P24354

Tumor-Associated Glycoprotein 72 (TAG-72)

Other Name(s): TAG-72

TAG-72: A Protein Interactor with Potential Cancer Treatments

Tumor-Associated Glycoprotein 72 (TAG-72) is a protein that is expressed in various types of cancer, including breast, lung, and ovarian cancer. It is a glycoprotein that is composed of a core protein and a glycosylated terminal region that contains a glycophosphoryl group. The glycophosphoryl group is a type of sugar molecule that is covalently bound to the protein, giving it a positive charge. This positive charge allows TAG-72 to interact with various cellular components and molecules, including other proteins and drugs.

One of the key features of TAG-72 is its ability to interact with the protein called sonic hedgehog (SHH), which is a transmembrane protein that is involved in cell signaling. SHH is a potent regulator of cell proliferation and has been implicated in the development and progression of many types of cancer. TAG-72 has been shown to interact with SHH and can inhibit its activity, which can lead to the inhibition of cell proliferation and the regression of cancer tumors.

Another feature of TAG-72 is its ability to interact with the protein called FAK, which is a protein that is involved in cell signaling and has been implicated in the development and progression of many types of cancer. TAG-72 has been shown to interact with FAK and can inhibit its activity, which can lead to the inhibition of cell proliferation and the regression of cancer tumors.

TAG-72 has also been shown to interact with the protein called PDGF-BB, which is a protein that is involved in cell signaling and has been implicated in the development and progression of many types of cancer. TAG-72 has been shown to interact with PDGF-BB and can inhibit its activity, which can lead to the inhibition of cell proliferation and the regression of cancer tumors.

In addition to its ability to interact with SHH, FAK, and PDGF-BB, TAG-72 has also been shown to interact with a number of other proteins, including the protein called NF-kappa-B, which is involved in cell signaling and has been implicated in the development and progression of many types of cancer. TAG-72 has been shown to interact with NF-kappa-B and can inhibit its activity, which can lead to the inhibition of cell proliferation and the regression of cancer tumors.

TAG-72 has also been shown to interact with the protein called TGF-β, which is involved in cell signaling and has been implicated in the development and progression of many types of cancer. TAG-72 has been shown to interact with TGF-β and can inhibit its activity, which can lead to the inhibition of cell proliferation and the regression of cancer tumors.

TAG-72 has also been shown to interact with the protein called SMAD, which is involved in cell signaling and has been implicated in the development and progression of many types of cancer. TAG-72 has been shown to interact with SMAD and can inhibit its activity, which can lead to the inhibition of cell proliferation and the regression of cancer tumors.

In conclusion, TAG-72 is a protein that has been shown to interact with a number of different proteins, including SHH, FAK, PDGF-BB, NF-kappa-B, TGF-β, and SMAD. These interactions suggest that TAG-72 may be a drug target or biomarker for the treatment of cancer. Further research is needed to confirm this and to determine the most effective way to use TAG-72 in the treatment of cancer.

Protein Name: Tumor-Associated Glycoprotein 72 (TAG-72)

The "Tumor-Associated Glycoprotein 72 (TAG-72) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Tumor-Associated Glycoprotein 72 (TAG-72) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets